We are live on ! Find out more
VRCA icon

Verrica Pharmaceuticals
VRCA

27 hedge funds and large institutions have $164M invested in Verrica Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 27 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

3.2% more ownership

Funds ownership: 0% → 3.2% (+3.2%)

Holders
27
Holders Change
+27
Holders Change %
–
% of All Funds
0.62%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
27
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
+$66.8M
2
O
OrbiMed
New York
+$29M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$21.5M
4
FI
Fosun International
China
+$15.6M
5
Fidelity International
Fidelity International
Bermuda
+$8.18M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
1
Perceptive Advisors
New York
$67.3M +$66.8M +341,041 New
O
2
OrbiMed
New York
$29.2M +$29M +147,973 New
Fidelity Investments
3
Fidelity Investments
Massachusetts
$21.7M +$21.5M +110,000 New
FI
4
Fosun International
China
$15.7M +$15.6M +79,600 New
Fidelity International
5
Fidelity International
Bermuda
$8.24M +$8.18M +41,759 New
GGHC
6
Gilder Gagnon Howe & Co
New York
$2.94M +$2.92M +14,904 New
KCM
7
Kornitzer Capital Management
Kansas
$2.9M +$2.88M +14,724 New
CI
8
Conning Inc
Connecticut
$2.58M +$2.56M +13,073 New
SFM
9
Sphera Funds Management
Israel
$2.48M +$2.46M +12,580 New
MIM
10
Monashee Investment Management
Massachusetts
$1.97M – – –
Alyeska Investment Group
11
Alyeska Investment Group
Illinois
$1.38M +$1.37M +7,005 New
ACM
12
Asymmetry Capital Management
California
$1.18M +$1.18M +6,000 New
Goldman Sachs
13
Goldman Sachs
New York
$1M +$993K +5,071 New
Wellington Management Group
14
Wellington Management Group
Massachusetts
$795K +$789K +4,028 New
OAM
15
Oxford Asset Management
United Kingdom
$772K +$770K +3,929 New
DIM
16
DC Investments Management
Virginia
$676K +$672K +3,429 New
Norges Bank
17
Norges Bank
Norway
$592K +$588K +3,000 New
PCM
18
Prelude Capital Management
New York
$592K +$588K +3,000 New
Vanguard Group
19
Vanguard Group
Pennsylvania
$549K +$545K +2,784 New
Millennium Management
20
Millennium Management
New York
$508K +$504K +2,575 New
LCM
21
Laurion Capital Management
New York
$395K +$392K +2,000 New
BCM
22
BlueCrest Capital Management
Jersey
$296K +$294K +1,500 New
CIAS
23
Capital Investment Advisory Services
North Carolina
$211K +$210K +1,070 New
Morgan Stanley
24
Morgan Stanley
New York
$47K +$47.2K +241 New
Royal Bank of Canada
25
Royal Bank of Canada
Ontario, Canada
$25K +$24.9K +127 New
1
2

VRCA Hedge Fund Activity: Q2 2018 in Review

27 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Verrica Pharmaceuticals (VRCA) for Q2 2018, worth a combined $164M.

Buyers outnumbered sellers: 27 funds opened new VRCA positions and 0 closed out — a net gain of 27 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Perceptive Advisors, opening a new position worth an estimated $66.8M.

  • 27 institutional investors held Verrica Pharmaceuticals (VRCA) as of Q2 2018, up from 0 in Q1 2018.
  • Funds reported $164M of Verrica Pharmaceuticals stock for Q2 2018.
  • 27 funds opened new Verrica Pharmaceuticals positions in Q2 2018 and 0 closed out, a net change of +27 holders.
  • The largest Verrica Pharmaceuticals buyer in Q2 2018 was Perceptive Advisors, an estimated $66.8M added.

Based on aggregated 13F filings for Q2 2018.